EP1014946A4 - Sustained-release liposomal anesthetic compositions - Google Patents

Sustained-release liposomal anesthetic compositions

Info

Publication number
EP1014946A4
EP1014946A4 EP98948352A EP98948352A EP1014946A4 EP 1014946 A4 EP1014946 A4 EP 1014946A4 EP 98948352 A EP98948352 A EP 98948352A EP 98948352 A EP98948352 A EP 98948352A EP 1014946 A4 EP1014946 A4 EP 1014946A4
Authority
EP
European Patent Office
Prior art keywords
anesthetic
local
encapsulated
sustained
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP98948352A
Other languages
German (de)
French (fr)
Other versions
EP1014946A1 (en
EP1014946B1 (en
Inventor
Sinil Kim
Taehee Kim
Sharad Murdandi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pacira Pharmaceuticals Inc
Original Assignee
Skyepharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skyepharma Inc filed Critical Skyepharma Inc
Priority to EP10003091A priority Critical patent/EP2198854B1/en
Priority to EP10183360A priority patent/EP2308470A1/en
Publication of EP1014946A1 publication Critical patent/EP1014946A1/en
Publication of EP1014946A4 publication Critical patent/EP1014946A4/en
Application granted granted Critical
Publication of EP1014946B1 publication Critical patent/EP1014946B1/en
Priority to CY20101100573T priority patent/CY1110135T1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides a method for obtaining local anesthetics encapsulated in liposomes, such as multivesicular liposomes, with high encapsulation efficiency and slow release in vivo. When the encapsulated anesthetic is administered as a single intracutaneous dose, the duration of anesthesia and half-life of the drug at the local injection site is increased as compared to injection of unencapsulated anesthetic. The maximum tolerated dose of the encapsulated anesthetic is also markedly increased in the liposomal formulation over injection of unencapsulated anesthetic. These results show that the liposomal formulation of local anesthetic is useful for sustained local infiltration and nerve block anesthesia.
EP98948352A 1997-09-18 1998-09-18 Sustained-release liposomal anesthetic compositions Expired - Lifetime EP1014946B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP10003091A EP2198854B1 (en) 1997-09-18 1998-09-18 Sustained-release liposomal anesthetic compositions
EP10183360A EP2308470A1 (en) 1997-09-18 1998-09-18 Sustained-release liposomal anesthetic compositions
CY20101100573T CY1110135T1 (en) 1997-09-18 2010-06-22 Liposomal Compositions of Anesthetic Prolonged Release

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5923397P 1997-09-18 1997-09-18
US59233 1997-09-18
PCT/US1998/019583 WO1999013865A1 (en) 1997-09-18 1998-09-18 Sustained-release liposomal anesthetic compositions

Publications (3)

Publication Number Publication Date
EP1014946A1 EP1014946A1 (en) 2000-07-05
EP1014946A4 true EP1014946A4 (en) 2006-05-17
EP1014946B1 EP1014946B1 (en) 2010-04-07

Family

ID=22021653

Family Applications (3)

Application Number Title Priority Date Filing Date
EP98948352A Expired - Lifetime EP1014946B1 (en) 1997-09-18 1998-09-18 Sustained-release liposomal anesthetic compositions
EP10183360A Withdrawn EP2308470A1 (en) 1997-09-18 1998-09-18 Sustained-release liposomal anesthetic compositions
EP10003091A Expired - Lifetime EP2198854B1 (en) 1997-09-18 1998-09-18 Sustained-release liposomal anesthetic compositions

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP10183360A Withdrawn EP2308470A1 (en) 1997-09-18 1998-09-18 Sustained-release liposomal anesthetic compositions
EP10003091A Expired - Lifetime EP2198854B1 (en) 1997-09-18 1998-09-18 Sustained-release liposomal anesthetic compositions

Country Status (16)

Country Link
US (5) US6045824A (en)
EP (3) EP1014946B1 (en)
JP (1) JP4467789B2 (en)
AT (2) ATE535232T1 (en)
AU (1) AU735588B2 (en)
CA (1) CA2304096C (en)
CY (1) CY1110135T1 (en)
DE (1) DE69841598D1 (en)
DK (1) DK1014946T3 (en)
ES (2) ES2343767T3 (en)
HK (1) HK1145966A1 (en)
IL (1) IL135060A (en)
NO (1) NO329727B1 (en)
NZ (1) NZ503513A (en)
PT (1) PT1014946E (en)
WO (1) WO1999013865A1 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2343767T3 (en) * 1997-09-18 2010-08-09 Pacira Pharmaceuticals, Inc. LIPOSOMIC ANESTHETIC COMPOSITIONS OF SUSTAINED LIBERATION.
WO1999025319A1 (en) * 1997-11-14 1999-05-27 Depotech Corporation Production of multivesicular liposomes
CA2375371A1 (en) * 1999-06-04 2000-12-14 Skyepharma Inc. Oil-core compositions for the sustained release of hydrophobic drugs
US6566575B1 (en) 2000-02-15 2003-05-20 3M Innovative Properties Company Patterned absorbent article for wound dressing
US6977323B1 (en) 2000-02-17 2005-12-20 3M Innovative Properties Company Foam-on-film medical articles
US6716186B1 (en) 2000-08-16 2004-04-06 3M Innovative Properties Company Curable adhesive splints and methods
US6903243B1 (en) 2000-09-08 2005-06-07 3M Innovative Properties Company Multi-layer absorbent wound dressing
CA2447990C (en) * 2001-05-31 2012-01-31 Skyepharma Inc. Encapsulation of nanosuspensions in liposomes and microspheres
US7476400B2 (en) * 2001-11-13 2009-01-13 Ferndale Ip, Inc. High-concentration lidocaine compositions and methods for their preparation
US7005143B2 (en) 2002-04-12 2006-02-28 3M Innovative Properties Company Gel materials, medical articles, and methods
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US7612248B2 (en) 2002-12-19 2009-11-03 3M Innovative Properties Company Absorbent medical articles
US20050070688A1 (en) 2003-09-26 2005-03-31 3M Innovative Properties Company Reactive hydrophilic oligomers
US7384984B2 (en) 2003-12-10 2008-06-10 3M Innovative Properties Company Reactive hydrophilic oligomers
US7074839B2 (en) 2004-03-01 2006-07-11 3M Innovative Properties Company Crosslinkable hydrophilic materials from reactive oligomers having pendent photoinitiator groups
US7342047B2 (en) 2004-03-02 2008-03-11 3M Innovative Properties Company Crosslinkable hydrophilic materials from reactive oligomers having pendent unsaturated groups
US20060029657A1 (en) * 2004-03-26 2006-02-09 Stiefel Laboratories, Inc. Topical skin protectant compositions
US8609131B2 (en) 2005-01-25 2013-12-17 3M Innovative Properties Company Absorbent dressing comprising hydrophilic polymer prepared via Michael reaction
US7335690B2 (en) 2005-01-25 2008-02-26 3M Innovative Properties Company Crosslinkable hydrophilic materials from polymers having pendent Michael donor groups
AU2007240317B2 (en) * 2006-04-20 2012-11-29 Amgen Inc. Stable emulsion formulations
US7981949B2 (en) 2006-05-23 2011-07-19 3M Innovative Properties Company Curable hydrophilic compositions
BRPI0812264B1 (en) * 2007-05-29 2016-01-26 Pola Chem Ind Inc gallbladder and external skin preparation
KR20120081938A (en) 2008-10-07 2012-07-20 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. Liposomal systems comprising sphingomyelin
US20100305500A1 (en) * 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
WO2011075623A1 (en) 2009-12-18 2011-06-23 Latitude Pharmaceuticals, Inc. One - phase gel compos ition compri s ing phos pholi pids
CN103002878B (en) 2010-04-09 2015-07-01 帕西拉制药有限公司 Method for formulating large diameter synthetic membrane vesicles
JP6194248B2 (en) 2010-10-28 2017-09-06 パシラ ファーマシューティカルズ インコーポレーテッド Sustained release formulations of non-steroidal anti-inflammatory drugs
GB201020860D0 (en) * 2010-12-09 2011-01-26 Univ Wolverhampton Disulfiram formulation and uses thereof
WO2013168172A1 (en) 2012-05-10 2013-11-14 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
WO2014046191A1 (en) * 2012-09-21 2014-03-27 テルモ株式会社 Local-anesthetic long-lasting sustained-release liposome preparation
WO2014134586A2 (en) 2013-02-28 2014-09-04 Mira Pharma Corporation Injectable long-acting local anesthetic semi-solid formulations and its compostions
US10220093B2 (en) 2013-02-28 2019-03-05 Mira Pharma Corporation Long-acting semi-solid lipid formulations
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
HUE052224T2 (en) 2014-04-21 2021-04-28 Heron Therapeutics Inc Compositions of a polyorthoester and an organic acid excipient
US10213510B2 (en) 2014-04-21 2019-02-26 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
EP3509601A1 (en) 2014-04-21 2019-07-17 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
CN110845355A (en) * 2015-01-06 2020-02-28 塞尔利克斯生物私人有限公司 Compositions and methods for treating inflammation and pain
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
AU2016256979B2 (en) 2015-05-04 2021-01-28 Versantis AG Method for preparing transmembrane pH-gradient vesicles
EP3317448B1 (en) 2015-06-30 2021-09-08 Tela Bio, Inc. Corner-lock stitch patterns
US10426587B2 (en) 2015-07-21 2019-10-01 Tela Bio, Inc. Compliance control stitching in substrate materials
CN105708820B (en) * 2016-03-25 2019-05-24 广州玻思韬控释药业有限公司 A kind of lipid-polymer microparticle formulation of local anesthetic and preparation method thereof
EP3448308B1 (en) 2016-04-26 2024-08-14 Tela Bio, Inc. Hernia repair grafts having anti-adhesion barriers
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
EP3541815A4 (en) 2016-11-18 2020-07-15 Pacira Pharmaceuticals, Inc. Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same
CA3048485C (en) * 2016-12-26 2022-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2018164121A1 (en) 2017-03-06 2018-09-13 丸石製薬株式会社 Acidic emulsion composition containing local anesthetic agent
WO2018207188A1 (en) * 2017-05-11 2018-11-15 Steadymed, Ltd. Enhanced solubility drug-containing formulations
LT3675816T (en) 2017-08-28 2023-06-26 Tlc Biopharmaceuticals, Inc. Sustained-release anesthetic compositions and methods of preparation thereof
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
AU2018345844B2 (en) 2017-10-06 2024-03-07 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
US11426418B2 (en) 2017-12-06 2022-08-30 Mira Pharma Corporation Injectable long-acting semi-solid gel formulations
US10561606B2 (en) 2017-12-06 2020-02-18 Mira Pharma Corporation Injectable long-acting local anesthetic semi-solid gel formulations
CN108158998B (en) * 2017-12-28 2021-01-26 广州玻思韬控释药业有限公司 Bupivacaine multivesicular liposome preparation facilities
CN108078929B (en) * 2017-12-28 2021-01-01 广州玻思韬控释药业有限公司 Preparation method of bupivacaine multivesicular liposome and bupivacaine multivesicular liposome preparation
EP3761963A4 (en) * 2018-03-09 2021-12-08 Tela Bio, Inc. Surgical repair graft
KR20200136990A (en) 2018-03-30 2020-12-08 티엘씨 바이오파머슈티컬즈 인코포레이티드 Sustained-release anesthetic composition and manufacturing method thereof
CN108354903A (en) * 2018-04-11 2018-08-03 西安力邦生物医药技术有限公司 A kind of regional anesthesia analgesia sustained release drug delivery systems and its preparation method and application
WO2020185688A1 (en) 2019-03-08 2020-09-17 Tela Bio, Inc. Textured medical textiles
CN113116823B (en) * 2019-12-30 2024-02-20 江苏恒瑞医药股份有限公司 Liposome and preparation method thereof
EP4087540A4 (en) * 2020-01-06 2024-01-10 Pacira Pharmaceuticals, Inc. Treatment of pain associated with cesarean section surgery with sustained-release liposomal anesthetic compositions
WO2021141959A1 (en) * 2020-01-10 2021-07-15 Pacira Pharmaceuticals, Inc. Treatment of pain by administration of sustained-release liposomal anesthetic compositions
CN115297854A (en) 2020-01-10 2022-11-04 帕西拉制药股份有限公司 Treatment of pain by administering a slow release liposomal anesthetic composition through the subarachnoid space
EP4090353A4 (en) 2020-01-13 2023-08-09 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN116997338A (en) 2021-01-11 2023-11-03 帕西拉制药股份有限公司 Treatment of hip pain with a slow-release liposomal anesthetic composition
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
WO2022159564A1 (en) * 2021-01-22 2022-07-28 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
KR102701064B1 (en) * 2021-03-04 2024-08-30 포항공과대학교 산학협력단 A manufacturing method for liposom drug delivery structure based on liposomal bupivacaine and slow release preparation
US11931459B2 (en) 2021-03-19 2024-03-19 Pacira Pharmaceuticals, Inc. Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions
CN117999100A (en) * 2021-10-14 2024-05-07 帕西拉制药有限公司 Polycystic liposome formulation of dexamethasone
US20230133849A1 (en) * 2021-10-14 2023-05-04 Pacira Pharmaceuticals, Inc. Bupivacaine multivesicular liposome formulations and uses thereof
WO2023164431A1 (en) * 2022-02-24 2023-08-31 Pacira Pharmaceuticals, Inc. Uses of bupivacaine multivesicular liposomes as stellate ganglion block
US11918565B1 (en) 2022-11-03 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions
WO2024102696A1 (en) * 2022-11-10 2024-05-16 Pacira Pharmaceuticals, Inc. Uses of bupivacaine multivesicular liposomes as stellate ganglion block for treating anxiety disorders and traumatic brain injury

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000888A1 (en) * 1991-07-03 1993-01-21 Vestar, Inc. Loading technique for preparing drug containing liposomes
WO1995013796A1 (en) * 1993-11-16 1995-05-26 Depotech Corporation Vesicles with controlled release of actives
WO1997003652A1 (en) * 1995-07-14 1997-02-06 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3684251A (en) 1970-09-08 1972-08-15 Us Army Apparatus for continuous emulsification
US3946994A (en) 1974-04-10 1976-03-30 Petrolite Corporation System for producing emulsions
IT1015665B (en) 1974-07-04 1977-05-20 Snam Progetti METHOD FOR THE PREPARATION IN WITH TINUE OF WATER OIL EMULSIONS AND EQUIPMENT SUITABLE FOR THE PURPOSE
CH588887A5 (en) 1974-07-19 1977-06-15 Battelle Memorial Institute
US4113765A (en) 1975-03-21 1978-09-12 Standard Oil Company (Indiana) Continuous process for sulfonating alkyl aromatics
US4897308A (en) 1975-06-30 1990-01-30 L'oreal Compositions comprising aqueous dispersions of lipid spheres
US4078052A (en) 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (en) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4310506A (en) 1979-02-22 1982-01-12 California Institute Of Technology Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
DE2909906A1 (en) 1979-03-14 1980-10-02 Bayer Ag METHOD FOR THE CONTINUOUS PRODUCTION OF MICROCAPSULES
US4235587A (en) 1979-04-09 1980-11-25 Honeywell Inc. Flame responsive control circuit
JPS55153713A (en) 1979-05-02 1980-11-29 Kureha Chem Ind Co Ltd Pharmaceutical preparation of ribosome containing active substance
JPS6127918Y2 (en) 1979-11-07 1986-08-19
US4394372A (en) 1980-12-22 1983-07-19 The Procter & Gamble Company Process for making lipid membrane structures
US4454083A (en) 1981-12-21 1984-06-12 Appleton Papers Inc. Continuous microencapsulation
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US5387410A (en) 1983-03-18 1995-02-07 Mallinckrodt, Inc. Method for enhancing magnetic resonance with compositions containing paramagnetic elements carried by liposomes
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
JPH0768117B2 (en) 1983-05-06 1995-07-26 ベスター・インコーポレイテツド Vesicle formulation for controlled drug release
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
FR2548043A1 (en) 1983-06-14 1985-01-04 Saint Gobain Vitrage METHOD AND DEVICE FOR CASTING MANUFACTURE OF TRANSPARENT OPTICALLY HOMOGENEOUS LAYER FROM COMPONENT MIXTURE
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4478824A (en) 1983-08-08 1984-10-23 Franco Robert S Method for altering red blood cell function and survival
JPS60100516A (en) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
US4599227A (en) 1983-11-07 1986-07-08 Wisconsin Alumni Research Foundation Injectable pharmaceutical preparation for the induction of multiple follicular growth
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4744989A (en) 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
EP0158441B2 (en) 1984-03-08 2001-04-04 Phares Pharmaceutical Research N.V. Liposome-forming composition
US5141674A (en) 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
US4610868A (en) 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
DE3421865A1 (en) 1984-06-13 1985-12-19 Bayer Ag, 5090 Leverkusen CONTINUOUS PRODUCTION OF MICROCAPSLE DISPERSIONS
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4761288A (en) 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
IE58981B1 (en) 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
ES2039203T3 (en) 1985-11-22 1993-09-16 Takeda Chemical Industries, Ltd. COMPOSITION OF LIPOSOMES.
US5244678A (en) * 1986-01-14 1993-09-14 Ire-Celltarg S.A. Pharmaceutical composition containing a local anesthetic and/or centrally acting analgesic encapsulated in liposomes
JPH0751496B2 (en) 1986-04-02 1995-06-05 武田薬品工業株式会社 Manufacturing method of liposome
DE3776966D1 (en) 1986-05-20 1992-04-09 Wako Pure Chem Ind Ltd FUNCTIONAL GROUPS OF LIPOSOME AND METHOD FOR THE PRODUCTION THEREOF.
US5204112A (en) 1986-06-16 1993-04-20 The Liposome Company, Inc. Induction of asymmetry in vesicles
US5147134A (en) 1986-08-21 1992-09-15 Petrolite Corporation Process for the continuous production of high-internal-phase-ratio emulsions
US4877619A (en) 1986-08-25 1989-10-31 Vestar, Inc. Liposomal vesicles for intraperitoneal administration of therapeutic agents
US4776991A (en) 1986-08-29 1988-10-11 The United States Of America As Represented By The Secretary Of The Navy Scaled-up production of liposome-encapsulated hemoglobin
US4752425A (en) 1986-09-18 1988-06-21 Liposome Technology, Inc. High-encapsulation liposome processing method
US4781871A (en) 1986-09-18 1988-11-01 Liposome Technology, Inc. High-concentration liposome processing method
US4844620A (en) 1986-11-24 1989-07-04 Petrolite Corporation System for producing high-internal-phase-ratio emulsion products on a continuous basis
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
GB8704171D0 (en) * 1987-02-23 1987-04-01 Clayton Found Res Multivesicular liposomes
US5723147A (en) 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
DK86988A (en) 1987-02-25 1988-08-26 Takeda Chemical Industries Ltd LIPOSOM PREPARATION AND APPLICATION THEREOF
JP2666345B2 (en) 1987-04-16 1997-10-22 武田薬品工業株式会社 Liposome preparation and method for producing the same
CA1337273C (en) 1987-07-29 1995-10-10 Robert P. Lenk Method for size separation of particles
JP2877160B2 (en) 1987-07-29 1999-03-31 ザ リポソーム カンパニー，インコーポレイテッド Separation method by particle size
US4946683A (en) 1987-11-18 1990-08-07 Vestar, Inc. Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes
IE63518B1 (en) 1987-11-18 1995-05-03 Vestar Inc Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes
US4921644A (en) 1988-02-29 1990-05-01 Technology Unlimited, Inc. Mucin directed lipsome
EP0331504B1 (en) 1988-03-04 1992-06-10 Takeda Chemical Industries, Ltd. Liposome composition
US5948441A (en) 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
US5261903A (en) 1988-04-11 1993-11-16 M.D. Inc. Composite anesthetic article and method of use
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US5576017A (en) 1988-05-30 1996-11-19 Depotech Corporation Heterovesicular liposomes
US4937078A (en) * 1988-08-26 1990-06-26 Mezei Associates Limited Liposomal local anesthetic and analgesic products
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
BE1001869A3 (en) 1988-10-12 1990-04-03 Franz Legros METHOD OF PACKAGING liposomal AMINOGLUCOSIDIQUES ANTIBIOTICS IN PARTICULAR THE GENTAMYCIN.
US4921853A (en) 1988-11-14 1990-05-01 Michigan State University Method for producing analgesia in mammals
US4908463A (en) 1988-12-05 1990-03-13 Ethyl Corporation Aluminoxane process
US5049392A (en) * 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
US5364632A (en) 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
US5227170A (en) 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5227165A (en) 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5334381A (en) 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5246707A (en) 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
US5091187A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5169934A (en) 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
USRE35192E (en) 1990-11-13 1996-03-26 Phoenix Surgical Products, Inc. Post-surgical anesthesia at a continuous and progressively decreasing administration rate
IS1685B (en) 1990-12-11 1998-02-24 Bracco International B.V. Method of making liposomes that are endowed with enhanced ability to absorb and contain foreign matter
SE506930C2 (en) 1991-03-25 1998-03-02 Svedala Pumps & Process Ab Method and apparatus for thickening fine particulate suspensions
US5885260A (en) 1991-05-30 1999-03-23 Mehl, Sr.; Thomas L. Freeze-dried liposome delivery system for application of skin treatment agents
US5977326A (en) 1991-08-06 1999-11-02 Salford Ultrafine Chemicals And Research Limited Process for making morphine-6-glucuronide or substituted morphine-6-glucuronide
SE9200952D0 (en) 1992-03-27 1992-03-27 Kabi Pharmacia Ab PHARMACEUTICAL CARRIER SYSTEM CONTAINING DEFINED LIPIDS
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
EP0665743B1 (en) 1992-10-14 2001-12-12 The Liposome Company, Inc. Interdigitation-fusion liposomes and gels
CA2146963A1 (en) 1992-10-16 1994-04-28 Andreas Sachse Process and device for producing liquid, dispersed systems
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
JPH06247842A (en) 1993-02-23 1994-09-06 Green Cross Corp:The Production of liposome composition
DE59406065D1 (en) 1993-03-24 1998-07-02 Ciba Geigy Ag Process for the production of a liposome dispersion in the high pressure range
EP0692961A1 (en) 1993-04-02 1996-01-24 The Liposome Company, Inc. Method of producing liposomes
US5891842A (en) 1993-04-09 1999-04-06 Trustees Of Tufts College Methodology for eliciting an analgesic response in a living subject
DK0695169T3 (en) 1993-04-22 2003-03-17 Skyepharma Inc Multivesicular liposomes with encapsulated cyclodextrin and pharmacologically active compounds and methods for using them
JPH09503743A (en) 1993-05-14 1997-04-15 デポテック コーポレーション How to treat neurological disorders
US5455044A (en) 1993-05-14 1995-10-03 Depotech Corporation Method for treating neurological disorders
WO1994026253A1 (en) 1993-05-19 1994-11-24 The Liposome Company, Inc. Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer
US5554382A (en) 1993-05-28 1996-09-10 Aphios Corporation Methods and apparatus for making liposomes
US5776486A (en) 1993-05-28 1998-07-07 Aphios Corporation Methods and apparatus for making liposomes containing hydrophobic drugs
US5425707A (en) * 1993-06-28 1995-06-20 Goldberg; Larry Method for non-surgical treatment of carpal tunnel syndrome
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5853755A (en) 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
GB9320668D0 (en) 1993-10-07 1993-11-24 Secr Defence Liposomes containing particulare materials
GB9321061D0 (en) 1993-10-13 1993-12-01 Chiroscience Ltd Analgestic agent and its use
US5849763A (en) 1993-10-13 1998-12-15 Darwin Discovery Limited Use of levobupivacaine as an anesthetic agent
WO1995010277A1 (en) 1993-10-13 1995-04-20 Chiroscience Limited Analgesic agent and its use
US5766627A (en) * 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5451408A (en) 1994-03-23 1995-09-19 Liposome Pain Management, Ltd. Pain management with liposome-encapsulated analgesic drugs
SE518578C2 (en) 1994-06-15 2002-10-29 Gs Dev Ab Lipid-based composition
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6048545A (en) * 1994-06-24 2000-04-11 Biozone Laboratories, Inc. Liposomal delivery by iontophoresis
US6066331A (en) 1994-07-08 2000-05-23 Barenholz; Yechezkel Method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers
SE9402453D0 (en) 1994-07-12 1994-07-12 Astra Ab New pharmaceutical preparation
DE4430592A1 (en) 1994-08-20 1996-02-22 Max Delbrueck Centrum Liposomal preparation, its preparation and its use
US5993850A (en) 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US5589189A (en) 1994-09-14 1996-12-31 Nexstar Pharmaceuticals, Inc. Liposome dispersion
US5702722A (en) 1994-09-30 1997-12-30 Bracco Research S.A. Liposomes with enhanced entrapment capacity, method and use
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
EP0808153B1 (en) 1995-02-10 1999-08-04 Medtronic, Inc. Method and device for administering analgesics
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
SE505146C2 (en) * 1995-10-19 1997-06-30 Biogram Ab Particles for delayed release
US6046187A (en) 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
WO1998016199A1 (en) 1996-10-15 1998-04-23 The Liposome Company, Inc. N-acyl phosphatidylethanolamine-mediated liposomal drug delivery
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
WO1998024415A1 (en) 1996-12-02 1998-06-11 The Regents Of The University Of California A bilayer structure which encapsulates multiple containment units and uses thereof
US5865184A (en) 1997-01-13 1999-02-02 Takiguchi; Tetsuo Combined spinal and epidural anesthesia
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US5864184A (en) * 1997-03-05 1999-01-26 Brian Page Platner Interface circuitry for facilitating installation of a control device
EP1201241B8 (en) 1997-03-13 2010-10-27 James N. Campbell Compositions containing capsaicin or capsaicin analogues and an anesthetic
US6306432B1 (en) 1997-09-08 2001-10-23 Chiron Corporation High and low load formulations of IGF-I in multivesicular liposomes
US6106858A (en) 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
ES2343767T3 (en) * 1997-09-18 2010-08-09 Pacira Pharmaceuticals, Inc. LIPOSOMIC ANESTHETIC COMPOSITIONS OF SUSTAINED LIBERATION.
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000888A1 (en) * 1991-07-03 1993-01-21 Vestar, Inc. Loading technique for preparing drug containing liposomes
WO1995013796A1 (en) * 1993-11-16 1995-05-26 Depotech Corporation Vesicles with controlled release of actives
WO1997003652A1 (en) * 1995-07-14 1997-02-06 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release

Also Published As

Publication number Publication date
US20130344132A1 (en) 2013-12-26
EP2198854A2 (en) 2010-06-23
CA2304096C (en) 2003-09-09
CY1110135T1 (en) 2015-01-14
US20060078606A1 (en) 2006-04-13
IL135060A (en) 2005-12-18
US6045824A (en) 2000-04-04
EP2198854B1 (en) 2011-11-30
EP1014946A1 (en) 2000-07-05
DE69841598D1 (en) 2010-05-20
ES2343767T3 (en) 2010-08-09
JP4467789B2 (en) 2010-05-26
AU9494298A (en) 1999-04-05
NO20001410L (en) 2000-05-15
US20120231070A1 (en) 2012-09-13
US8182835B2 (en) 2012-05-22
EP2198854A3 (en) 2011-01-05
WO1999013865A1 (en) 1999-03-25
ATE535232T1 (en) 2011-12-15
CA2304096A1 (en) 1999-03-25
US9192575B2 (en) 2015-11-24
PT1014946E (en) 2010-07-06
US8834921B2 (en) 2014-09-16
HK1145966A1 (en) 2011-05-13
DK1014946T3 (en) 2010-06-28
JP2001516714A (en) 2001-10-02
NZ503513A (en) 2004-12-24
EP1014946B1 (en) 2010-04-07
ES2373861T3 (en) 2012-02-09
IL135060A0 (en) 2001-05-20
ATE463238T1 (en) 2010-04-15
NO329727B1 (en) 2010-11-30
AU735588B2 (en) 2001-07-12
US20130189349A1 (en) 2013-07-25
EP2308470A1 (en) 2011-04-13
NO20001410D0 (en) 2000-03-17
US9205052B2 (en) 2015-12-08

Similar Documents

Publication Publication Date Title
HK1145966A1 (en) Sustained-release liposomal anesthetic compositions
NO20022014L (en) A solid oral controlled release dosage form containing hydrocodone
CA2503810A1 (en) Therapeutic agent for fibromyalgia
AU1534699A (en) Osmotic dosage form comprising first and second coats
GR3036798T3 (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
AU1046302A (en) Transdermal therapeutic system
ZA973444B (en) Transdermally administered dextromethorphan as antitussive agents.
CA2454699A1 (en) Method for treating primary insomnia
DK408188A (en) INJECTABLE AGENT FOR CONTROLLED RELEASE OF OPIOID ANALYSIS
WO1998036778A8 (en) Sustained drug delivery and compositions useful therefor
UA30654A (en) Method for treatment of posttraumatic disfunctions of temporomandibular joint

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000418

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SKYEPHARMA INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20060403

17Q First examination report despatched

Effective date: 20070508

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PACIRA PHARMACEUTICALS, INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69841598

Country of ref document: DE

Date of ref document: 20100520

Kind code of ref document: P

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: KIRKER & CIE S.A.

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20100628

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20100401480

Country of ref document: GR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2343767

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20110110

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20170911

Year of fee payment: 20

Ref country code: CH

Payment date: 20170912

Year of fee payment: 20

Ref country code: GB

Payment date: 20170913

Year of fee payment: 20

Ref country code: GR

Payment date: 20170810

Year of fee payment: 20

Ref country code: LU

Payment date: 20170908

Year of fee payment: 20

Ref country code: IT

Payment date: 20170925

Year of fee payment: 20

Ref country code: FR

Payment date: 20170810

Year of fee payment: 20

Ref country code: DE

Payment date: 20170912

Year of fee payment: 20

Ref country code: MC

Payment date: 20170728

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20170825

Year of fee payment: 20

Ref country code: DK

Payment date: 20170912

Year of fee payment: 20

Ref country code: PT

Payment date: 20170918

Year of fee payment: 20

Ref country code: NL

Payment date: 20170919

Year of fee payment: 20

Ref country code: IE

Payment date: 20170912

Year of fee payment: 20

Ref country code: SE

Payment date: 20170912

Year of fee payment: 20

Ref country code: BE

Payment date: 20170724

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20170807

Year of fee payment: 20

Ref country code: ES

Payment date: 20171002

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69841598

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20180917

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Effective date: 20180918

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20180917

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20180918

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 463238

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180918

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20180917

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20180918

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20181003

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20211229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20180919